Kevin Rakin

Sciona, Inc. provides health and nutrition recommendations. It researches and develops DNA screens for common gene variants that affect an individual's response to food, medications and the environment. These genetic screens serve as the basis for providing personalized advice to consumers. The company was founded by Rosalynn Gill-Garrison and Gareth Roberts on June 8, 2000 and is headquartered in Boulder, CO.

Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland.

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

Canaan Management, Inc. (Canaan Management) is a venture capital firm founded in 1987 by Eric A. Young. The firm is headquartered in Westport, CT.

QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France.

Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.

HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut..

Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to: correct mutations, leading to restoration of normal function of key gene products, alter levels of gene expression, potentially turning genes on or off, functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells. Through the use of SBIR grants and seed funding, it will advance preclinical projects targeting the human globin gene for applications on sickle cell anemia and beta-thalassemia, the CCR5 receptor for the HIV/AIDS population, and genetic mutations responsible for the liposomal storage disease, Gaucher's. Genetic alteration of stem cells has the potential to dramatically impact the efficacy of stem cell therapy for human disease. Due to the accessibility of HSC without bone marrow transplants, the company is currently focused on blood based genetic diseases. As advances in human stem cell biology are realized, however, it is possible to envision applications in a broad array of human genetic diseases. Moreover, because the DNA modifications introduced to stem cells are stable and heritable; this technology offers the hope of curing certain genetic diseases. Its approach does not rely on viral vectors and corrects the patients own cells, eliminating potential immune reactions. This approach is classified as Cellular Therapy, which provides another level of safety to the patient.

HighCape Capital Acquisition Corp. II operates as a blank check company. Its objective is effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on February 9, 2021 and is headquartered in New York, NY.

HighCape Capital LP is a growth equity fund based in New York, NY. HighCape Capital is dedicated to helping innovative life sciences companies transition into successful and thriving organizations. HighCape Capital LP was founded in 2013 by Kevin L. Rakin and he has been the CEO since 2013.

Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT.

HighCape Capital Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on June 10, 2020 and is headquartered in New York, NY.

Collagen Matrix, Inc. design and manufactures extracellular matrices for tissue and organ repair and regeneration. The firm offers collagen and mineral-based finished medical devices in the areas of orthopedic-spine surgery, neurosurgery, oral surgery, and wound care. It provides DuraMatrix, Neuroflex, NeuroMatrix, OssiMend, and the Matrix Collagen. The company was founded by Shu-Tung Li in 1997 and is headquartered in Oakland, NJ.

Wellinks, Inc. provides wearable health technology services. It engages in improving clinical outcomes through education and creation of good habits around treatment. The company was founded by Ellen Su, Sebastian Monzon and Levi Deluke and is headquartered in New Haven, CT.